Mathilde Latil
Responsable de la biologie et pharmacologie experimentale at Biophytis - New Therapeutics for aging diseases | Greater Paris Metropolitan Region, France
Mathilde Latil’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Responsable de la biologie et pharmacologie experimentale at Biophytis - New Therapeutics for aging diseases in July 2017 - Present
Chef de projet Oncologie - Post Doctorat at Université libre de Bruxelles in March 2013 - December 2016
PhD, Doctorat en Biologie cellulaire et moléculaire at Institut Pasteur in September 2009 - February 2013
Institut Pasteur Paris, PhD en biologie cellulaire et moléculaire
Université Paris-Est, Master 2 Biothérapies Tissulaires, Cellulaires et géniques
Université Paris-Est Créteil (UPEC), Master 1
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, with promising results in a Phase 2 clinical study (SARA) conducted in the United States and Europe A pediatric formulation of Ruvembri is being developed with IND granted in the US and Belgium (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD).
Discover more about Biophytis - New Therapeutics for aging diseases
Chief Pharmaceutical Operations / QA Director / QP / Development, Innovation & Strategy / Natural Products-Essential Oils Expert/ Facilitator/Professional Mentor
RA strategy senior external consultant throughout IDD (medical device) at NEMERA
(July 2026 – July 2026)
PhD. in Immunology. Clinical research Lead at Biophytis - New Therapeutics for diseases of aging.
Clinical research Lead at Biophytis - LIVE HEALTHIER LONGER
(November 2022 – Present)
Clinical development for unmet medical needs
Clinical Monitoring Manager at Merck Serono
(July 2026 – July 2026)
Senior Manager, CMC
Senior Manager, CMC Regulatory Affairs at DBV Technologies
(July 2026 – July 2026)
CMC & Pharmaceutical Development Manager
CMC & Pharmaceutical Development Manager at Biophytis - LIVE HEALTHIER LONGER
(February 2021 – Present)
Translational and clinical research project leader in neuromuscular diseases at Biophytis
Translational and clinical research project leader in neuromuscular diseases at Biophytis - LIVE HEALTHIER LONGER
(February 2018 – Present)
What is Mathilde Latil email address?
Email Mathilde Latil at [email protected]. This email is the most updated Mathilde Latil's email found in 2026.
How to contact Mathilde Latil?
To contact Mathilde Latil send an email to [email protected].
What company does Mathilde Latil work for?
Mathilde Latil works for Biophytis - New Therapeutics for aging diseases.
What is Mathilde Latil's role at Biophytis - New Therapeutics for aging diseases?
Mathilde Latil is Responsable de la biologie et pharmacologie experimentale
What industry does Mathilde Latil work in?
Mathilde Latil works in the Research industry.
